#1 Clinical Trials Search in Europe

Clostridium Botulinum, Neurotoxin Serotype A/B

A new clinical trial is underway to investigate the safety and effectiveness of a modified botulinum neurotoxin, known as IPN10200, for treating moderate to severe upper facial lines. This study aims to compare IPN10200 with a placebo in improving the appearance of glabellar lines, forehead lines, and lateral canthal lines. The trial will assess various doses of the treatment and evaluate its impact on participants’ facial appearance over time.

Table of Contents

What is IPN10200?

IPN10200 is a new medication being studied for the treatment of moderate to severe upper facial lines. It is a type of botulinum neurotoxin, which is a protein produced by the bacterium Clostridium botulinum. This medication is also known as “CLOSTRIDIUM BOTULINUM, NEUROTOXIN SEROTYPE A/B” or “Modified recombinant botulinum neurotoxin serotype AB”[1].

Medical Conditions Treated

IPN10200 is being investigated for the treatment of moderate to severe upper facial lines, including:

  • Glabellar lines (GL): These are the vertical lines that appear between your eyebrows when you frown, often called “frown lines”[1].
  • Forehead lines (FHL): These are the horizontal lines that appear across your forehead when you raise your eyebrows.
  • Lateral canthal lines (LCL): These are the lines that appear at the outer corners of your eyes when you smile, often called “crow’s feet”.

How IPN10200 Works

IPN10200 is a neurotoxin that works by temporarily paralyzing specific muscles in the face. When injected into the targeted areas, it blocks nerve signals to the muscles, reducing their ability to contract. This results in a smoother appearance of the skin and a reduction in the visibility of wrinkles and lines[1].

Clinical Trial Details

A clinical trial is currently being conducted to assess the safety and effectiveness of IPN10200. This is a Phase Ib/II trial, which means it’s in the early stages of testing in humans. The trial is designed to:

  1. Evaluate the safety and tolerability of different doses of IPN10200
  2. Assess how well IPN10200 works in improving the appearance of upper facial lines
  3. Compare IPN10200 to a placebo (a treatment with no active ingredients)

The trial will measure the effects of the treatment using both the Investigator’s Live Assessment (ILA) and the Subject’s Self-assessment (SSA). These are tools used to grade the severity of facial lines[1].

Eligibility Criteria

To participate in this clinical trial, individuals must meet certain criteria. Some key requirements include:

  • Age: 18 to 65 years old
  • Having moderate to severe glabellar lines, forehead lines, and/or lateral canthal lines
  • Being dissatisfied with their facial lines
  • Not having had certain facial treatments or surgeries recently
  • Not having certain medical conditions that could interfere with the study

There are also specific criteria for women of childbearing potential regarding contraception use[1].

Safety and Efficacy

The main goals of this clinical trial are to assess the safety and efficacy of IPN10200. Researchers will be looking at:

  • The occurrence and severity of side effects
  • How well the treatment improves the appearance of facial lines
  • How quickly the treatment starts working
  • How long the effects of the treatment last
  • Patient satisfaction with the treatment

The study will also monitor for the development of antibodies against IPN10200, which could potentially affect its effectiveness[1].

Administration

IPN10200 is administered as an intramuscular injection. This means it’s injected directly into the muscles responsible for facial expressions. The exact dosage and injection sites will depend on which facial lines are being treated[1].

Potential Side Effects

As with any medical treatment, there may be side effects. The clinical trial will carefully monitor participants for any adverse events. Some potential side effects based on similar treatments might include:

  • Temporary weakness or paralysis of nearby muscles
  • Headache
  • Bruising or swelling at the injection site
  • Drooping eyelids (ptosis)

It’s important to note that the purpose of this clinical trial is to better understand the safety profile of IPN10200, so all potential side effects are not yet known[1].

Aspect Details
Study Drug IPN10200 (Modified recombinant botulinum neurotoxin serotype A/B)
Study Type Phase Ib/II, multicentre, double-blind, randomized, placebo-controlled
Primary Objectives Assess safety, tolerability, and efficacy of IPN10200 in improving moderate to severe upper facial lines
Target Population Adults aged 18-65 with moderate to severe upper facial lines
Key Assessments Investigator’s Live Assessment (ILA), Subject’s Self-assessment (SSA), safety monitoring
Duration of Effect To be determined based on ILA and SSA at maximum contraction during follow-up visits
Safety Measures Monitoring of adverse events, physical examinations, vital signs, antibody development

FAQ

  • What is IPN10200? IPN10200 is a modified recombinant botulinum neurotoxin serotype A/B, which is being studied for its potential to improve the appearance of moderate to severe upper facial lines.
  • What are the main objectives of this clinical trial? The main objectives are to assess the safety and tolerability of increasing doses of IPN10200 compared to placebo, and to evaluate its efficacy in improving the appearance of moderate to severe upper facial lines.
  • Who can participate in this clinical trial? Participants must be between 18 and 65 years old, have moderate to severe upper facial lines, and meet specific criteria regarding their facial appearance and overall health. Some exclusions apply, such as recent botulinum toxin treatments or certain medical conditions.
  • How will the effectiveness of IPN10200 be measured? The effectiveness will be measured using the Investigator's Live Assessment (ILA) and Subject's Self-assessment (SSA) at maximum contraction of facial muscles. The study will also assess the time to onset of treatment response and duration of effect.
  • What are the potential risks of participating in this trial? As with any clinical trial, there may be risks associated with the treatment. The study will closely monitor for any adverse events, including those specific to botulinum toxin treatments. Participants will undergo regular safety assessments throughout the trial.

Ongoing Clinical Trials on Clostridium Botulinum, Neurotoxin Serotype A/B

  • Corabotase for Moderate to Severe Glabellar Lines in Adults

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France Germany

  • Study on IPN10200 for Treating Cervical Dystonia in Adults

    Recruiting

    2 1
    Investigated drugs:
    Czechia France Germany Italy Poland Spain

  • Study on the Safety and Effectiveness of IPN10200 and Botulinum Toxin Type A for Adults with Moderate to Severe Upper Facial Lines

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany

  • Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

    Recruiting

    2 1 1
    Investigated drugs:
    Austria Bulgaria Czechia France Germany Hungary +4

  • Study of IPN10200 compared to placebo for prevention of episodic or chronic migraine in adults

    Not recruiting

    2 1
    Investigated drugs:
    Czechia France Germany Poland Spain

Glossary

  • Botulinum Neurotoxin: A protein produced by the bacterium Clostridium botulinum, which can temporarily paralyze muscles. In cosmetic applications, it's used to reduce the appearance of facial wrinkles.
  • Glabellar Lines (GL): Vertical lines that appear between the eyebrows, often called frown lines.
  • Forehead Lines (FHL): Horizontal lines that appear across the forehead.
  • Lateral Canthal Lines (LCL): Lines that appear at the outer corners of the eyes, often called crow's feet.
  • Investigator's Live Assessment (ILA): A method used by researchers to evaluate the appearance of facial lines during the study.
  • Subject's Self-assessment (SSA): A method where participants evaluate their own facial appearance during the study.
  • Placebo: An inactive substance used as a control in clinical trials to compare with the effects of the actual treatment being studied.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ipn10200-and-botulinum-toxin-type-a-for-adults-with-moderate-to-severe-upper-facial-lines/